News | June 15, 2024
Jubilant Draximage to invest US$ 50 million to expand its PET radiopharmacy network
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
To accelerate the development of next-generation radioconjugates to treat cancer
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
The initiative, “Change the Odds: Uniting to Improve Cancer Outcomes” aims to enhance awareness of and access to cancer screening, clinical trials and support
This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India
Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer
Comprehensive clinical development programs being initiated for each investigational candidate
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer
Subscribe To Our Newsletter & Stay Updated
